RE:Target Revisited One Last TimeCould we just cut out the BS please! Even MBI in their 'Prospectus' is honest about the competition faced in this market. It's just as likely at this point that GeneLungFx could fail as succeed. Consider that this test was developed in 2008 and what technological advancments have taken place in the field of Genomics since then. The statments below are from MBI:
Many of Precision’s competitors have financial, marketing and human resource assets greater than theirs, and there can be no assurance that Precision can successfully compete with such competitors or that such competition will not have a materially adverse effect on MBI’s licensing revenues.
The technologies associated with the molecular diagnostics industry are evolving rapidly and there is intense competition within such industry. Certain molecular diagnostics companies have established technologies that may be competitive to LungExpress Dx. Some of these tests may use different approaches or means to obtain diagnostic results, which could be more effective or less expensive than
tests for similar indications.
Moreover, these and other future competitors have or may have considerably
greater resources than Precision does in terms of technology, sales, marketing, commercialization and
capital resources.